MedTrace Logo

Clinical Value of Next Generation Sequencing in Chinese Childhood Solid Tumors

NCT05076071 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-10-13

No results posted yet for this study

Summary

Samples of 200 patients with pediatric malignant solid tumors will prospectively be collected. Selected samples are sufficient for next generation sequencing(NGS) and available for follow-up information. Multi-omics techniques such as DNA and RNA panel will be used to study driver genes for the development of malignant solid tumors in children, and to explore the pathogenic mechanism. The aim of this study is to explore new biomarkers for the diagnosis and treatment for childhood malignant solid tumors.

Conditions

  • Pediatric, Solid Tumors, NGS

Interventions

GENETIC

NGS

Next Generation Sequencing

Sponsors & Collaborators

  • Yizhuo Zhang

    lead OTHER

Eligibility

Min Age
0 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-06
Primary Completion
2023-07-06
Completion
2023-08-06

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05076071 on ClinicalTrials.gov